Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Naoto Sassa
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favourable/Intermediate Risk: Multicentre Randomised Trial CROSS-J-RCC
Clinical Genitourinary Cancer
Oncology
Urology
Related publications
Sunitinib Induced Cytopenia in Metastatic RCC
Clinical Medical Reviews and Case Reports
Rare Case of Tubulocystic RCC in Association With Papillary RCC
BMJ Case Reports
Medicine
Randomized, Phase II Trial of Sequential Hepatic Arterial Infusion Chemotherapy and Sorafenib Versus Sorafenib Alone as Initial Therapy for Advanced Hepatocellular Carcinoma: SCOOP-2 Trial
BMC Cancer
Cancer Research
Oncology
Genetics
RCC With Cavo-Atrial Extensions
Japanese Journal of Urology
Urology
Laparoscopic Cholecystectomy Versus Percutaneous Catheter Drainage for Acute Cholecystitis in High Risk Patients (CHOCOLATE): Multicentre Randomised Clinical Trial
British Medical Journal
Medicine
Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to the Bone Using Stereotactic Body Radiation Therapy: Is RCC Truly Radioresistant?
Practical Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
Two-Drug Cocktail Active Against RCC
Cancer Discovery
Oncology
PCN10 Targeted Therapy (TT) for First Line Treatment of Advanced Renal Cell Carcinoma (RCC): An Indirect Comparison Meta-Analysis (ICMA)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
The Lancet
Medicine
